Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Stock Short Interest Report for September

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 3,807 shares, a decline of 42.4% from the September 15th total of 6,607 shares. Based on an average daily trading volume, of 63,910 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.3% of the company’s shares are sold short.

Institutional Investors Weigh In On Regentis Biomaterials

An institutional investor recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC purchased a new stake in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned 5.79% of Regentis Biomaterials as of its most recent filing with the SEC.

Regentis Biomaterials Price Performance

Shares of NYSEAMERICAN RGNT traded up $0.03 on Thursday, hitting $1.54. The company had a trading volume of 12,398 shares, compared to its average volume of 1,756,675. The business has a 50 day moving average of $1.92 and a two-hundred day moving average of $2.50. Regentis Biomaterials has a 12-month low of $1.23 and a 12-month high of $15.50.

Regentis Biomaterials (NYSEAMERICAN:RGNT) last issued its quarterly earnings data on Friday, September 11th. The company reported ($0.22) earnings per share (EPS) for the quarter.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is an Israel-based biotechnology company focused on developing biomaterial-based solutions for the repair and regeneration of damaged cartilage. The company’s work is aimed primarily at orthopedic applications, including the treatment of focal cartilage defects in the knee.

Regentis’ lead product is GelrinC, a synthetic, cell-free hydrogel implant designed to fill cartilage lesions and support the formation of new tissue. The implant is intended to be delivered during a minimally invasive procedure and gradually integrate with the surrounding joint environment as the repair process progresses.

The company’s activities center on research, clinical development, regulatory advancement and potential commercialization of its cartilage-repair technology.